Heather Gwen MacK

Dr. Heather Gwen MacK

orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JSJudy Savige
Judy Savige
SSShivanand Sheth
Shivanand Sheth
ALAnita Leys
Anita Leys
ANAnjali Nicholson
Anjali Nicholson
HMHeather Gwen MacK
Heather Gwen MacK
DCDeb Colville
Deb Colville
Alport syndrome is an inherited disease characterized by progressive renal failure, hearing loss, and ocular abnormalities. Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive) genes result in absence of the collagen IV α3α4α5 network from the basement membranes of the cornea, lens capsule, and retina and are associated with corneal opacities, anterior lenticonus, fleck retinopathy, and temporal retinal thinning. Typically, these features do not affect vision or, in the case of lenticonus, are correctable. In contrast, the rarer ophthalmic complications of posterior polymorphous corneal dystrophy, giant macular hole, and maculopathy all produce visual loss. Many of the ocular features of Alport syndrome are common, easily recognizable, and thus, helpful diagnostically, and in identifying the likelihood of early-onset renal failure. Lenticonus and central fleck retinopathy strongly suggest the diagnosis of Alport syndrome and are associated with renal failure before the age of 30 years, in males with X-linked disease. Sometimes, ophthalmic features suggest the mode of inheritance. A peripheral retinopathy in the mother of a male with hematuria suggests X-linked inheritance, and central retinopathy or lenticonus in a female means that recessive disease is likely. Ocular examination, retinal photography, and optical coherence tomography are widely available, safe, fast, inexpensive, and acceptable to patients. Ocular examination is particularly helpful in the diagnosis of Alport syndrome when genetic testing is not readily available or the results are inconclusive. It also detects complications, such as macular hole, for which new treatments are emerging.

25 February 2016 in Ophthalmic Genetics
Verified
Journal Article
Closed access
PDF file
JSJ. Savige
J. Savige
LAL. Amos
L. Amos
FIFrank Ierino
Frank Ierino
HMHeather Gwen MacK
Heather Gwen MacK
RSR. C. Andrew Symons
R. C. Andrew Symons
DCD. Colville
D. Colville
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications.

1 February 2017 in MedEdPublish
Verified
Journal Article
Open access
PDF file
HMHeather Gwen MacK
Heather Gwen MacK
KGKarl C Golnik
Karl C Golnik
NMNeil Murray
Neil Murray
HFHelena P Filipe
Helena P Filipe
This article was migrated. The article was marked as recommended. Implementing CPD programs for medical professionals has been demonstrated to improve patient outcomes, and is increasingly required for continuing medical licensure. However, implementing programs in low-resource settings is challenging. This review has identified 5 different models for implementation: 1) twinning, 2) greenfield, 3) formal program guided by international medical bodies, 4) directed by regulators and 5) informal program guided by international medical bodies. The models, advantages and disadvantages and costs are discussed. There is minimal evidence on success of implementation models, and further studies are necessary.

1 January 1997 in International Ophthalmology Clinics
Verified
Journal Article
Closed access
HMHeather Gwen MacK
Heather Gwen MacK
FJFrederick A. Jakobiec
Frederick A. Jakobiec
Isolated metastases to the retina or optic nerve are extremely rare. Retinal metastases arise from cutaneous malignant melanoma and carcinomas (lung, gastrointestinal, genitourinary, and breast). Most patients present with reduced vision. The clinical appearance of these metastases is variable. Melanoma metastases are brown or black, whereas carcinoma metastases are white. Frequently, retinal hemorrhages and exudates are seen. Optic nerve metastases arise from carcinomas (lung, breast, and gastrointestinal) in adults and acute leukemias in children. As is true of retinal metastases, most patients present with reduced vision. Though in most cases there is a visible optic nerve mass, some patients have optic disc edema only. Investigations are directed by a known history of malignancy in many patients and by physical examination. Cytological workup of vitreous may be required. Treatment options include observation, radiotherapy in eyes with visual potential, and enucleation for pain control. The visual prognosis is poor. In patients with retinal or optic nerve metastases, median survival is approximately 9 months after the onset of visual symptoms, but is slightly longer in cases in which the primary lesion is breast carcinoma.

29 July 2020 in The Clinical Teacher
Verified
Journal Article
Closed access
PDF file
HFHelena Prior Filipe
Helena Prior Filipe
MPMorag Paton
Morag Paton
JTJane Tipping
Jane Tipping
SSSuzan Schneeweiss
Suzan Schneeweiss
HMHeather Gwen MacK
Heather Gwen MacK

1 April 2022 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
GAGocuk Sena A.
Gocuk Sena A.
YJYuanzhang Jiao
Yuanzhang Jiao
ABAlexis Ceecee Britten-Jones
Alexis Ceecee Britten-Jones
NKNathan Kerr
Nathan Kerr
LLLyndell Lim
Lyndell Lim
HMHeather Gwen MacK
Heather Gwen MacK
Background: To assess the prevalence of genetic testing for inherited retinal diseases (IRDs) in a tertiary practice setting. Methods: Single-centre retrospective analysis of patients with diagnosed or suspected IRD. Results: Four hundred and sixty-four patient records were analysed. Patients had received care for different IRDs grouped as follows: panretinal pigmentary retinopathies (283, 61%), macular dystrophies (136, 29.3%), stationary diseases (23, 5%), hereditary vitreoretinopathies (14, 3%), and other IRDs (8, 1.7%). The suspected pattern of inheritance of patients’ IRD was predominantly autosomal recessive (205, 44.2%). Genetic testing was performed with the corresponding results available for 44 patients (9.5%). Diagnostic yield was 65.9% for the results received. Genetic test results were available mostly for younger patients (13.1% for < 45 years vs 6.2% ≥ 45 years of age, p = 0.01) and those who received greater than 12 months of care (16% for ≥ 12 months vs 4% for < 12 months, p < 0.01). For patients without genetic testing results, reasons include awaiting a geneticist consultation (17.9%), awaiting test results (4.5%), or patient refusal (8.4%). Most clinical records (69.2%) did not document genetic testing status. Conclusion: Genetic testing is increasingly being utilised in the work-up for patients with IRD worldwide. This large Australian private practice IRD cohort shows a low uptake of testing (around 10%), reflecting historical management patterns and accessibility of genetic counselling and testing. The results show that younger patients and those with a longer duration of care were more likely to have received genetic testing. As the importance of IRD genetic testing continues to increase, we expect to see a change in patient management within the Australian private ophthalmology system and testing rates to increase. Further research is required to identify and address clinician and patient barriers to improving genetic testing rates for IRD.